BioPharma Dive May 31, 2024
Dubbed mResvia, the shot is cleared for use in older adults to prevent disease caused by RSV, a respiratory virus that circulates widely in the fall and winter.
The Food and Drug Administration on Friday approved a third vaccine for respiratory syncytial virus, clearing a shot from biotechnology company Moderna one year after granting a green light to vaccines from GSK and Pfizer.
The vaccine, dubbed mResvia, is for the prevention of disease caused by respiratory syncytial virus, or RSV, in adults 60 years of age and older. Experts from the Centers for Disease Control and Prevention are expected to meet next month to provide recommendations on the shot’s use. Moderna had said it expects the vaccine to be available...
Today's Sponsors
Today's Sponsor